N-(1,3-benzodioxol-5-ylmethyl)-2-methylpropanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: N-(1,3-benzodioxol-5-ylmethyl)-2-methylpropanamide
• 化学式: C₁₂H₁₅NO₃
• mdl: MFCD03383252
• 分子量: 221.25
• InChiKey: XCDYYDBJCCNOAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Heterocyclic inhibitors of ERK2 and uses thereof
  申请人：Cao Jingrong

  公开号：US20070265263A1

  公开（公告）日：2007-11-15

  Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein Z 1 and Z 2 are each independently nitrogen or CH and Ring A, T m R 1 , QR 2 , U n R 3 , and Sp are as described in the specification. The compounds are especially useful as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.

  本文介绍了一些具有下列式的蛋白激酶抑制剂的化合物： 其中Z1和Z2各自独立地为氮或CH，环A、TmR1、QR2、UnR3和Sp如说明书所述。这些化合物特别适用于抑制ERK2并治疗哺乳动物中由蛋白激酶抑制剂缓解的疾病，特别是癌症、炎症性疾病、再狭窄、糖尿病和心血管疾病等疾病。
• Alpha helix mimetics and methods relating thereto
  申请人：PRISM BioLab Co., Ltd.

  公开号：US10017522B2

  公开（公告）日：2018-07-10

  Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

  本发明公开了由式（I）表示的α-螺旋拟态结构和化合物（其中通式和各符号的定义如说明书中所定义）、与之相关的化学库以及与之相关的方法。进一步公开了这些化合物在治疗医疗条件（例如癌症疾病、纤维化疾病）中的应用，以及包含该拟态化合物的药物组合物。
• CELL-PROTECTIVE COMPOUNDS AND THEIR USE
  申请人：ETH ZÜRICH

  公开号：US20190343802A1

  公开（公告）日：2019-11-14

  The present invention is directed to cell-protective, in particular, cardio- and renal-protective organic compounds, preferably to organic compounds that inhibit substrate phosphorylation by the G-protein-coupled receptor kinase 2 (GRK2, ADRBK1). Preferably, the organic compounds inhibit the GRK2-mediated phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1, ASF-1, SF2) and/or phosducin for treating hypertension, heart diseases, heart dysfunction or failure and heart disease-associated pathologies, e.g. cardiomyocyte necrosis, ischemic cardiac disease and/or ischemic heart damage or ageing. Furthermore, the present invention is directed to a method for the identification of inhibitors of the (GRK2)-mediated phosphorylation of (SRSF1) and/or phosducin.
• COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES
  申请人：ETH ZURICH

  公开号：US20210015793A1

  公开（公告）日：2021-01-21

  The present invention is directed to compounds and corresponding pharmaceutical formulations for use in the medical treatment of CNS- and neurodegenerative diseases, for example, for use in the treatment and prophylaxis of familial or sporadic Alzheimer's disease. The invention further relates to corresponding methods of treatment and to a method for determining treatment progression or outcome of senescence and anti-aging treatment based on the detection and/or quantification of Membrane Palmitoylated Protein 1 (MPP1).
• US7253187B2
  申请人：——

  公开号：US7253187B2

  公开（公告）日：2007-08-07